As we navigate the choppy seas of the biotech industry, two significant players emerge from the fog, offering potential harbors of opportunity for investors: CRISPR Therapeutics (NASDAQ: CRSP) and Regeneron Pharmaceuticals (NASDAQ: REGN). While both have experienced a challenging trailing-12-month period, their futures are far from bleak.
Regeneron, in particular, shines brightly in this regard. Its flagship product, Dupixent, co-marketed with Sanofi, continues to fuel the company’s growth trajectory, exhibiting a robust 19% increase in sales to a remarkable $3.67 billion. The momentum generated by Dupixent is a testament to Regeneron’s strategic acumen and Sanofi’s marketing prowess.
However, this is not the full picture. The recent label expansions for Dupixent, such as for Chronic Obstructive Pulmonary Disease (COPD), are further expected to turbocharge revenue. The strategic decision to broaden its label indicates that Regeneron is not content to rest on its laurels – it is proactively seeking further growth opportunities.
On the other hand, CRISPR Therapeutics presents a more complex, but potentially rewarding investment thesis. Skepticism towards CRISPR’s prospects is understandable. Despite having a product on the market – a gene editing therapy called Casgevy developed in partnership with Vertex Pharmaceuticals – it is yet to generate significant revenue.
The process of administering Casgevy to patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT) is intricate and time-consuming, posing a considerable challenge. However, it is crucial to note that these are precisely the kind of hurdles that groundbreaking therapies like Casgevy have to overcome in their early stages.
Furthermore, CRISPR’s unprofitability might deter some investors, especially considering the uncertain economic landscape we are currently navigating. But let’s not forget that financial profitability in the biotech industry often follows a non-linear path, particularly for companies that are on the cutting edge of therapeutic innovation.
In conclusion, the biotech landscape is never devoid of investment opportunities, even in the face of adversity. Regeneron, with its strong growth driver Dupixent and strategic label expansions, is a testament to the rewards that a well-executed strategy can reap. CRISPR, despite some challenges, offers a glimpse into the potential future of medicine and may reward patient investors. As we continue to traverse these tumultuous times, the wisdom of long-term investment strategies in robust biotech companies like these becomes increasingly clear.
Read more from aol.com
